Tyra Biosciences, Inc
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
* Participants ≥ 18 years of age at the time of informed consent and willing and able to comply with all required study procedures * Confirmed LG UTUC (both favorable and unfavorable) per AUA * At least 5mm of marker lesion(s) left behind * Identification of marker lesion(s) within 8 weeks prior to randomization (refer to Inclusion Criterion #2) * If synchronous NMIBC, NMIBC must be fully resected and low-grade Ta or T1 * No prior BCG administration within 1 year of date of consent. * No intravesical chemotherapy within 8 weeks prior to C1D1 (including UGN-101). * No systemic chemotherapy with…
Self-administered 60mg dose Oral tablet(s) given daily
Self-administered 80mg dose Oral tablet(s) given daily